Simon Fricker has over 25 years of experience in the biopharmaceutical industry. Simon obtained his training in the UK with a Ph.D. in Chemistry and Molecular Science from the University of Warwickand postdoctoral training at the University of Cambridge. As a successful leader of pharmaceutical R&D he has worked in small company and large multi-national corporate environments, in the UK, Canada and USA. He was a member of the UK team which was awarded the Queen’s Award for Technology for the discovery of the cancer drug Paraplatin™. Simon was a founding member and Director of Biology of a Canadian biopharma company AnorMED taking two drugs into clinical development with IND filing in FDA divisions of virology (HIV) and oncology and the subsequent NDA and clinical approval of Mozobil™, a CXCR4 antagonist for hematopoietic stem cell mobilization for patients with multiple myeloma and non-Hodgkin’s lymphoma. As a Distinguished Scientific Fellow at the sanofi/Genzyme, R&D Center he led a research team working on immune-mediated diseases. He generated projects on chemokine receptor pharmacology for autoimmune and oncology diseases, and held a strategic role to identify innovative concepts for targeting multiple sclerosis. Simon has been the science lead on out-licensing and in-licensing business development opportunities. Currently Simon is an independent consultant to biopharma.
